Notre portefeuille de produits

Nos indications principales

Médicament
Préclinique
Phase 1
Phase 2
Phase 3
PDN / DHPB
Phase
RyplazimMD
Carence Congénitale
Fezagepras (PBI-4050)
Syndrome d’Alström
Fezagepras (PBI-4050)
Respiratory Fibrotic Diseases e.g. Fibrose Pulmonaire Idiopathique (FPI)
PBI-4547
Ph 1 suspended to analyze PK data & MOA
GPR84 Antagonist
Undisclosed
Respiratory/GI
Undisclosed
NASH
Undisclosed
Kidney